{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-014905","form_type":"8-K","ticker":"KAPA","cik":"0001962011","company_name":"Kairos Pharma, LTD.","filed_at":"2025-06-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.581563+00:00","generated_at":"2026-05-19T11:28:08.971769+00:00","sec_items":["1.01","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Kairos Pharma shareholders approve dilutive stock issuance, elect directors, enter IR pact","bullets":["Entered one-year IR services agreement with Barretto Pacific Corp for $170,000 fee.","Shareholders elected all four director nominees (Yu, Bae, Keyoung, Sighvi).","Ratified Weinberg & Company as independent auditor for FY2025.","Approved issuance of >20% common stock at price below NYSE American minimum price.","Advisory votes approved executive compensation and 1-year frequency."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-014905","json":"https://secwatch.observer/filing/0001641172-25-014905.json","markdown":"https://secwatch.observer/filing/0001641172-25-014905.md","text":"https://secwatch.observer/filing/0001641172-25-014905.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1962011/000164117225014905/0001641172-25-014905-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1962011/000164117225014905/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T11:28:08.971769+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}